Latest RedHill Biopharma News & Updates

See the latest news and media coverage for RedHill. We track all announcements, press releases, and industry mentions in real time, all in one place.

RedHill Biopharma (RedHill)

Specialty pharmaceutical company

redhillbio.com

Headquarters: Raleigh, United States
Founded year: 2009
Company type: Public company
Number of employees: 50–200

Last updated Today

Latest news about RedHill Biopharma (RedHill)

In short: RedHill Biopharma expanded its ADS offering, reported its 2025 financial results, and advanced its pipeline for oncology and GI indications.

Company announcements

April 30 RedHill

RedHill's RHB-204 shows comparable MAP killing efficacy to RHB-104

Efficacy was achieved with lower doses of two active ingredients, indicating potential for reduced toxicity and side effects.

April 27 RedHill

RedHill reports 2025 financial results and operational highlights

The company announced strategic partnerships, pipeline progress, and a court ruling, ending with positive equity.

April 22 RedHill

RedHill's opaganib enhances neuroblastoma chemo and augments TNBC immunity

New data presented at AACR 2026 show opaganib enhances oxaliplatin/doxorubicin in neuroblastoma and potentiates STING activation in triple-negative breast cancer.

February 25 RedHill

RedHill commences joint U.S. commercialization of Talicia

The full sales and operational launch under the agreement with Cumberland has started to support accelerated market penetration.

Media coverage

April 30 Morningstar

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease | Morningstar

RHB-204 is patent protected through ... and EU Orphan Designation (eligibility for 10 years EU market exclusivity) for NTM disease caused by MAC5 · The...

April 27 Stock Titan

Going concern warning at RedHill Biopharma (NASDAQ: RDHL) amid cash strain

Unless the context otherwise requires, ... Biopharma Ltd. and its wholly owned subsidiary, RedHill Biopharma Inc. (“RedHill U.S.”). The term “including” means “including but not...

April 22 GuruFocus

RedHill Biopharma (RDHL) Unveils Promising Preclinical Data at AACR

There has been no insider buying or selling activity reported in the last 12 months, indicating a lack of insider engagement with the stock at...

January 5 Stock Titan

RedHill Biopharma advances RHB-102 for GLP-1 GI side effects | RDHL Stock News

Development planned under the ... oral therapy for GLP-1/GIP receptor agonist therapy-associated GI side effects. Phase 2 Proof-of-Concept study designed, and intellectual property expanded ...

Never miss news about RedHill

Track RedHill and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.